May 10, 2022

Fusion Pharmaceuticals Announces First Quarter 2022 Financial Results And Clinical Program Updates

Phase 1 data for FPI-1434 anticipated to be reported in the second half of 2022 Company continues to build a diversified pipeline of TATs and advance manufacturing and actinium...
Read more
May 10, 2022

Targovax and Oslo University Hospital announce collaboration to test TG mutant RAS vaccination in multiple myeloma

Targovax has entered into an agreement with Oslo University Hospital (OUS) to test TG01 in a phase 1/2 trial in 20 patients with RAS mutant multiple myelomaThe trial will be spons...
Read more
May 6, 2022

Nordic Nanovector ASA: Invitation to First Quarter 2022 Results Presentation and Webcast

Oslo, Norway, 6 May 2022 Nordic Nanovector ASA (OSE: NANOV) announces that it will report its results for the first quarter 2022 on Friday, 13 May 2022. A presentation by No...
Read more
May 5, 2022

Interim report January – March 2022

Gothenburg, May 5, 2022 - Vicore Pharma Holding AB (publ) publishes the interim report for the first quarter 2022. Important events during the first quarter In February, an ...
Read more
May 4, 2022

Xeris Biopharma to Report First Quarter 2022 Financial Results on May 11, 2022

Conference call and webcast at 8:30am ET CHICAGO--(BUSINESS WIRE)--May 4, 2022-- Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a biopharmaceutical company devel...
Read more
May 4, 2022

BONESUPPORT Holding AB (publ) – Publishes Q1 2022 interim report

Published: 2022-05-04 BONESUPPORT Holding AB (publ), a leading company in orthobiologics for the management of bone injuries, today publishes the interim report for the first q...
Read more
May 4, 2022

Oncopeptides publishes Q1 report 2022

STOCKHOLM — May 4, 2022 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematologi...
Read more
May 3, 2022

Pulmonx Reports First Quarter 2022 Financial Results

REDWOOD CITY, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lu...
Read more
May 3, 2022

Adcendo Appoints Dominik Mumberg, PhD, as Chief Scientific Officer

Brings in-depth R&D expertise in oncology, including ADCs, targeted radiotherapies, immunooncology and small moleculesAdcendo building a world class team of experienced biotec...
Read more
May 3, 2022

Nordic Nanovector: New Publication Highlights Synergistic Potential of CD37-targeted Radioimmunoconjugate Humalutin® in Combination with the PARP-inhibitor Olaparib

Second publication reports on CD37-targeting imaging approach to select NHL patients who might respond best to Humalutin® treatment  Oslo, Norway, 3 May 2022 Nordic Na...
Read more